Nancy A Dawson
Overview
Explore the profile of Nancy A Dawson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
2196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaudian K, Koh M, Koh M, Collins R, Eden S, Zwart Z, et al.
Front Oncol
. 2025 Feb;
15:1540482.
PMID: 39949742
Introduction: Injectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy (RT). Relugolix is an oral GnRH receptor antagonist that achieves rapid testosterone suppression. Non-adherence...
2.
Koh M, Koh M, Hsueh J, Gallagher L, Danner M, Zwart A, et al.
Front Oncol
. 2025 Feb;
14:1496646.
PMID: 39896185
Introduction: Studies have demonstrated that injectable GnRH receptor agonists further suppress cancer progression when paired with radiotherapy (RT) in patients with intermediate- to high-risk prostate adenocarcinoma. Relugolix is a newly...
3.
Hsueh J, Gallagher L, Koh M, Shah S, Danner M, Zwart A, et al.
Front Oncol
. 2024 Aug;
14:1412786.
PMID: 39188681
Introduction: Androgen deprivation therapy has been shown to improve cancer control when combined with radiotherapy. Relugolix is an oral GnRH receptor antagonist that achieves rapid profound testosterone suppression, which may...
4.
Hsueh J, Gallagher L, Koh M, Eden S, Shah S, Wells M, et al.
Front Oncol
. 2024 Apr;
14:1377103.
PMID: 38665954
Introduction: Sexual function following local treatment for prostate cancer is an important quality of life concern. Relugolix is a novel oral GnRH receptor antagonist used in combination with radiation therapy...
5.
Barata P, Gulati S, Elliott A, Hammers H, Burgess E, Gartrell B, et al.
J Clin Invest
. 2024 Apr;
134(11).
PMID: 38652565
Molecular profiling of clear cell renal cell carcinoma (ccRCC) tumors of patients in a clinical trial has identified distinct transcriptomic signatures with predictive value, yet data in non-clear cell variants...
6.
Shah S, Pepin A, Jatar S, Hsueh J, Gallagher L, Danner M, et al.
Cureus
. 2024 Apr;
16(3):e55729.
PMID: 38586683
Background: Androgen deprivation therapy (ADT) improves local cancer control in unfavorable localized prostate cancer treated with radiotherapy. ADT is known to cause hormonally related symptoms that resolve with testosterone recovery....
7.
Gallagher L, Xiao J, Hsueh J, Shah S, Danner M, Zwart A, et al.
Front Oncol
. 2023 Nov;
13:1289249.
PMID: 37916156
Introduction: Injectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy. Prostate SBRT offers an abbreviated treatment course with comparable efficacy to conventionally fractionated radiotherapy....
8.
Kemeny M, Zhao F, Forastiere A, Catalano P, Hamilton S, Miedema B, et al.
Ann Surg Oncol
. 2022 Oct;
30(2):1099-1109.
PMID: 36305992
Background: Studies suggest that adjuvant chemotherapy should be initiated at the earliest possible time. The Eastern Cooperative Oncology Group (ECOG) and Intergroup evaluated the effect of perioperative fluorouracil (5-FU) on...
9.
Sarker D, Dawson N, Aparicio A, Dorff T, Pantuck A, Vaishampayan U, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5248-5257.
PMID: 34281912
Purpose: In patients with metastatic castration-resistant prostate cancer (mCRPC), resistance to androgen receptor (AR)-targeted therapies, such as enzalutamide, remains an issue. Inactivation of inhibitory PTEN activates PI3K/AKT signaling and contributes...
10.
Rentz A, Mansukhani S, Liu J, Lloyd A, Heidenreich S, Matza L, et al.
Urol Oncol
. 2021 Mar;
39(6):367.e7-367.e17.
PMID: 33736976
Purpose: Men with castration-resistant prostate cancer (CRPC) experience disease progression at different rates. The purpose of this study was to quantify the strength of patient preferences for delaying prostate cancer...